Results 111 to 120 of about 1,651 (200)

Editorial: Targeted alpha particle therapy in oncology

Frontiers in Medicine, 2023
Øyvind Sverre Bruland, Øyvind Sverre Bruland, Roy Hartvig Larsen, Richard Paul Baum, Asta Juzeniene, Asta Juzeniene   +5 more
doaj   +1 more source

Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial

EJNMMI Radiopharmacy and Chemistry
Background The alpha emitter astatine-211 (211At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (131I).
Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato, Noriyuki Tomiyama, Tadashi Watabe   +11 more
doaj   +1 more source

CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model [PDF]

Stefan Radtke, Kyle Swing, George S. Laszlo, Andrea Repele, Greta Kanestrom, Nicholas Petty, Donald K. Hamlin, D. Scott Wilbur, Brenda M. Sandmaier, Hans‐Peter Kiem, Roland B. Walter   +10 more
openalex   +1 more source

UEG Week 2025 Moderated Posters

United European Gastroenterology Journal, Volume 13, Issue S8, Page S189-S802, October 2025.
wiley   +1 more source

Radiolabeling yield dependency of post-dry distillation decay of astatine-211

Nuclear Medicine and Biology
Astatine-211 (211At) is one of the most promising nuclides for targeted alpha therapy. However, while several clinical trials are ongoing worldwide, some aspects of the element remain unexplored. This work aims to investigate changes in radiochemical yield over time, expressed as the number of 211At decays, post-dry distillation using two common ...
Ellinor, Hansson, Chiara, Timperanza, Holger, Jensen, Björn, Eriksson, Sture, Lindegren, Emma, Aneheim   +5 more
openaire   +2 more sources

Lead-212 Radiopharmaceuticals for Receptor-Targeted Radionuclide Therapy [PDF]

Journal of Mazandaran University of Medical Sciences
Receptor-targeted radionuclide therapy (RTRT) combines the power of particle-emitting radionuclides with the receptor-targeting capabilities of biomolecules, including antibodies and peptides.
Solmaz Mojarad-Jabali, Sajjad Molavipordanjani   +1 more
doaj  

Alpha particle emitters in medicine [PDF]

, 1989
Radiation-induced cancer of bone, liver and lung has been a prominent harmful side-effect of medical applications of alpha emitters. In recent years, however, the potential use of antibodies labeled with alpha emitting radionuclides against cancer has ...
Fisher, D. R.
core  

Enhancing Radionuclide Production Capabilities at the Duke University Medical Center Cyclotron with a Focus on Astatine-211

, 2023
Michael R. Zalutsky
openalex   +1 more source

THE INDUCTION OF TUMORS IN THE RAT BY ASTATINE-211 [PDF]

, 1957
Patricia W. Durbin, C. Willet Asling, Muriel E. Johnston   +2 more
openalex   +1 more source

Exploration of new radiolabelling pathways with nucleophilic astatine-211 : application to the preparation of radioimmunoconjugates for targeted alpha therapy of cancers

, 2020
Marion Berdal
openalex   +1 more source